Adam Miner, MD
Family Medicine · Richardson, TXNPI 1467454603
Payments from drug & device makers
Across 246 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$717
- Lilly USA, LLC$544
- Amarin Pharma, Inc.$388
- GSK$372
- AbbVie$361
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$180%
- Food & beverage$5,07398%
- Education$852%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $1,299 |
| AstraZeneca | 39 | $717 |
| Lilly USA, LLC | 31 | $544 |
| Amarin Pharma, Inc. | 21 | $388 |
| GSK | 5 | $372 |
| AbbVie(2 entities) | 17 | $361 |
| Abbott | 6 | $149 |
| Johnson & Johnson | 4 | $132 |
| Boehringer Ingelheim | 7 | $114 |
| Pfizer | 5 | $103 |
| Bayer | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Eisai Inc. | 4 | $78 |
| Dexcom, Inc. | 4 | $76 |
| Medtronic | 1 | $63 |
| Amneal Pharmaceuticals LLC | 4 | $61 |
| Merck | 2 | $51 |
| Amgen | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Exact Sciences | 2 | $46 |
| Aytu Biopharma, Inc. | 2 | $32 |
| Althera Pharmaceuticals LLC | 2 | $30 |
| Novartis | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Si-bone, Inc. | 1 | $23 |
| Gilead | 1 | $23 |
| Adlon Therapeutics L.p. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Renalytix AI, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Medicure Pharma Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Optos, Inc. | 1 | $16 |
| Linus Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,191 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $86,441 |
| FarxigaDapagliflozin Propanediol | 46 | $66,838 |
| VascepaIcosapent Ethyl | 61 | $51,732 |
| JardianceEmpagliflozin | 21 | $24,570 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,879 |
| TradjentaLinagliptin | 21 | $21,561 |
| EliquisApixaban | 19 | $19,109 |
| JanuviaSitagliptin Phosphate | 22 | $17,250 |
| NamzaricMemantine Hcl/Donepezil Hcl | 16 | $12,192 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $11,416 |
| Bydureon BciseExenatide Microspheres | 13 | $10,890 |
| SynthroidLevothyroxine Sodium | 103 | $9,779 |
| EntrestoSacubitril/Valsartan | 13 | $9,220 |
| XareltoRivaroxaban | 13 | $8,959 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,299 | $86,44160 claims |
| AstraZenecaFarxiga, Symbicort | $717 | $69,31757 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $114 | $51,84853 claims |
| MerckJanuvia, Janumet | $51 | $28,66736 claims |
| AbbVieNamzaric, Synthroid | $361 | $21,971119 claims |
| PfizerEliquis, Paxlovid | $103 | $21,96839 claims |
| GSKTrelegy Ellipta | $372 | $21,87922 claims |
| NovartisEntresto | $29 | $9,22013 claims |
| Johnson & JohnsonXarelto | $132 | $8,95913 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $61 | $1,955202 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Richardson
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.